Skip to main content
. Author manuscript; available in PMC: 2019 Jan 24.
Published in final edited form as: J Med Chem. 2018 May 7;61(10):4593–4607. doi: 10.1021/acs.jmedchem.8b00389

Figure 1.

Figure 1.

Overview of furoxan development for the CNS. The furoxans described here have more favorable physiochemical properties as potential CNS drugs than previously described furoxans. Furoxans have not been studied in the brain previously. *Abbreviations: MW = molecular weight; tPSA = total polar surface area; cLogP = calculated partition coefficient; Aβ = oligomeric amyloid beta; LTP = long-term potentiation; STPA = step-through passive avoidance.